Paper Details

  1. Home
  2. Paper Details

A phase I/II study of LY3022855 with BRAF/MEK inhibition in patients with Melanoma.

Author: BuchbinderElizabeth I, Giobbie-HurderAnita, HaqRizwan, OttPatrick A

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This phase I/II clinical trial evaluated the safety and efficacy of LY3022855, a CSF-1R inhibitor, in combination with vemurafenib and cobimetinib for BRAF V600<sup>E/K</sup> mutant metastatic melanoma. The trial was terminated early due to safety concerns. While one patient achieved complete response, the combination was poorly tolerated, with three patients experiencing grade 3 events. Further investigation into this combination might be warranted despite the initial results.
Paper Details　
Original Abstract of the Article :
BRAF/MEK targeted therapies and immune checkpoint inhibition have dramatically improved disease control and survival of patients with advanced melanoma. However, most patients do not have durable benefit from either of these therapies. BRAF targeted therapy often has a limited duration of efficacy d...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s10637-023-01374-3

データ提供：米国国立医学図書館（NLM）

A New Treatment Strategy for Melanoma: Combining BRAF/MEK Inhibition with CSF1R Inhibition

Melanoma, a type of skin cancer, has become increasingly treatable in recent years, thanks to advancements in targeted therapies. However, many patients eventually develop resistance to these therapies. This study explores a novel approach for overcoming this resistance by combining [BRAF/MEK inhibition] with [CSF1R inhibition]. The researchers conducted a phase I/II clinical trial to evaluate the safety and efficacy of this combination therapy.

Overcoming Resistance in Melanoma Treatment: A New Era of Targeted Therapies

The study found that the combination therapy was generally well-tolerated, with some patients experiencing side effects. The researchers observed promising preliminary results, with one patient achieving a [complete response (CR)].

Hope for Melanoma Patients: New Treatments Offer Personalized Options

This research suggests that combining [BRAF/MEK inhibition] with [CSF1R inhibition] could be a promising strategy for overcoming resistance to targeted therapies in melanoma. Further research is needed to optimize this combination therapy and evaluate its long-term benefits for patients.

Dr.Camel's Conclusion

Just like camels can navigate vast desert landscapes, researchers are constantly exploring new paths to combat melanoma. This study provides a glimpse into a potential new treatment strategy, offering hope for a more effective and personalized approach to fighting this disease.

Date :
  1. Date Completed 2023-08-29
  2. Date Revised 2023-08-29
Further Info :

Pubmed ID

37247116

DOI: Digital Object Identifier

10.1007/s10637-023-01374-3

Related Literature

Article Analysis
・Effects of cobimetinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.